Last checked at 8 Oct 2015 07:00
08 October 2015
Avacta Group plc
("Avacta" or "the Group")
Notice of Results
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, expects to announce its preliminary results for the year ended 31 July 2015 on Monday 26 October 2015.
Enquiries:
Avacta Group plc Alastair Smith, Chief Executive Officer Tim Sykes, Chief Financial Officer | Tel: +44 (0) 844 414 0452 www.avacta.com |
Numis Securities Limited Michael Meade / Freddie Barnfield - Nominated Adviser James Black - Corporate Broking
WG Partners David Wilson Nigel Barnes Claes Spang
| Tel: +44 (0) 207 260 1000 www.numiscorp.com
Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217 www.wgpartners.co.uk
|
Media Enquiries FTI Consulting Simon Conway/Natalie Garland-Collins | Tel: +44 (0) 20 3727 1000 avacta@fticonsulting.com |
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimers have been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimers are based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta is commercialising Affimer reagents through custom Affimer services to provide bespoke solutions to customers, via a growing on-line catalogue of Affimer reagents and, in the longer term, by developing Affimers with therapeutic properties for out-licensing.